Elsevier

The Lancet

Volume 374, Issue 9698, 17–23 October 2009, Pages 1312-1313
The Lancet

Comment
Possible harms of oseltamivir—a call for urgent action

https://doi.org/10.1016/S0140-6736(09)61804-3Get rights and content

References (8)

  • T Yorifuji et al.

    Oseltamivir and abnormal behaviours: true or not?

    Epidemiology

    (2009)
  • R Hama

    Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships

    Int J Risk Safety Med

    (2008)
  • T Jefferson et al.

    Neuraminidase inhibitors for preventing and treating influenza in healthy adults

    Cochrane Database Syst Rev

    (2006)
  • M Shun-Shin et al.

    Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

    BMJ

    (2009)
There are more references available in the full text version of this article.

Cited by (34)

  • Influenza-existing drugs and treatment prospects

    2022, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Oseltamivir (F1) was very popular among physicians from July 2004 to June 2009. As more than 11.5 million new prescriptions were issued in the US [18]. Since 75% of the world's production of Oseltamivir (F1) has been used in Japan, in 2005, the Japanese ministry of health labor and welfare funded a cohort study to gain comprehensive knowledge about Oseltamivir (F1) in the larger population [19,20].

  • During influenza season: All influenza-like illnesses are not due to influenza: Dengue mimicking influenza

    2015, Journal of Emergency Medicine
    Citation Excerpt :

    Rash is uncommon with adult influenza and when it occurs in children it is usually maculopapular and truncal and does not usually involve the extremities. It was thought that because of the pruritic nature of the rash, that it could be due to the neuraminidase inhibitor that she was taking (4–6). Although cutaneous and neurologic adverse side effects of oseltamivir are most common in children, it was not unreasonable to consider that the rash was a possible cutaneous manifestation of oseltamivir.

  • EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo

    2012, Antiviral Research
    Citation Excerpt :

    While during the 2008/2009 season, up to 99% of seasonal H1N1 strains were resistant to oseltamivir (Centers for Disease Control and Prevention, 2009; Sheu et al., 2011), pandemic H1N1 shows a low percentage of oseltamivir-resistant strains so far (Hayden and de Jong, 2011), even though resistant clusters have emerged recently (Hurt et al., 2011). Although oseltamivir is generally well tolerated (Jackson et al., 2011; Matheson et al., 2007), side effects like abnormal behavior or delirium have been observed in children and adolescents (Jefferson et al., 2009) or adults (Nakamura et al., 2010). These problems highlight the need for new, effective and well tolerated antiviral drugs.

  • Antiviral drugs

    2011, Side Effects of Drugs Annual
    Citation Excerpt :

    Mild neuropsychiatric adverse effects were reported by 18% of the children. It is still not clear what the balance of benefit to harm is in this case [261cr]. Oseltamivir phosphate is an ethyl ester prodrug that is hydrolysed by carboxylesterase 1 (CES1) to an active metabolite, oseltamivir carboxylate.

View all citing articles on Scopus
View full text